Senzo

Senzo is a private, pre-revenue diagnostics company pioneering a high-sensitivity lateral flow technology designed to bridge the gap between laboratory PCR and rapid antigen tests. Its core innovation, the Amplified Lateral Flow (ALF) platform, claims over 10,000 times more sensitivity than standard lateral flow tests and accuracy comparable to PCR, targeting the WHO's A.S.S.U.R.E.D. criteria for ideal point-of-care diagnostics. The company is advancing a pipeline of tests for major infectious diseases and has secured strategic manufacturing partnerships and funding to commercialize its platform for both professional and home use.

Amplified Lateral Flow (ALF) platform: A proprietary lateral flow assay technology claiming over 10,000x more sensitivity than standard lateral flow tests and accuracy equivalent to laboratory PCR, delivering results in 10 minutes in a point-of-care format.

Senzo competes in the crowded rapid diagnostics space, facing off against standard lateral flow test manufacturers (e.g., Abbott, Roche, Quidel) and companies developing molecular point-of-care systems (e.g., Cepheid, Lucira). Its unique proposition is combining PCR-level sensitivity with the simplicity and low cost of a basic lateral flow strip, a claim that, if validated, would differentiate it from both categories.